Domov › Rakovina vaječníkov › Kalifornia › San Diego
Klinické štúdie Rakovina vaječníkov v meste San Diego, CA
24 štúdií pre Rakovina vaječníkov hľadá účastníkov v zariadeniach v meste San Diego a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Prebieha náborFáza 2
- UC San Diego Medical Center - Hillcrest, San Diego
- Sharp Memorial Hospital, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 míľ odtiaľ
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Prebieha náborFáza 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 míľ odtiaľ
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Prebieha náborFáza 1/2
- University of San Diego Moores Cancer Center, La Jolla · 11 míľ odtiaľ
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Prebieha náborFáza 2
- Scripps Md Anderson - Prebys Cancer Center /ID# 276891, San Diego
DESTINY-PANTUMOUR04
Prebieha náborObservačná štúdia
- Research Site, San Diego
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Prebieha náborObservačná štúdia
- University of California San Diego, La Jolla · 11 míľ odtiaľ
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Prebieha náborFáza 3
- Moores Cancer Center, La Jolla · 11 míľ odtiaľ
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Prebieha náborFáza 2
- UC San Diego Health - Moores Cancer Center /ID# 277574, La Jolla · 11 míľ odtiaľ
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Prebieha náborFáza 3
- University of California, San Diego-Moores Cancer Center, La Jolla · 11 míľ odtiaľ
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Prebieha náborFáza 2
- Scripps Healthscripps Mercy Hospital Prebys Cancer Center, San Diego
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Prebieha náborObservačná štúdia
- University of California, San Diego, La Jolla · 11 míľ odtiaľ
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Prebieha náborFáza 2
- UC San Diego Health, La Jolla · 11 míľ odtiaľ
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Prebieha náborFáza 1
- Scripps Health, San Diego
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Prebieha náborFáza 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 míľ odtiaľ
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Prebieha náborFáza 1
- UC San Diego Moores Cancer Center, La Jolla · 11 míľ odtiaľ
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Prebieha náborFáza 3
- UC San Diego Health - Moores Cancer Center, La Jolla · 11 míľ odtiaľ
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Prebieha náborFáza 3
- Kaiser Permanente-San Diego Zion, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 míľ odtiaľ
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Prebieha náborFáza 1/2
- University of California, San Diego; Moores Cancer Center, San Diego
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1
- Investigative Site #101, La Jolla · 11 míľ odtiaľ
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Prebieha náborFáza 3
- Scripps Clinic, La Jolla · 11 míľ odtiaľ
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Prebieha náborFáza 1/2
- UCSD Moores Cancer Center, La Jolla · 11 míľ odtiaľ
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Prebieha náborFáza 3
- University of California San Diego Moores Cancer Center, La Jolla · 11 míľ odtiaľ
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prebieha náborObservačná štúdia
- Massive Bio SYNERGY-AI site, La Jolla · 11 míľ odtiaľ
A Beta-only IL-2 ImmunoTherapY Study
Prebieha náborFáza 1/2
- Sharp Memorial Hospital, San Diego
Štúdie Rakovina vaječníkov v iných mestách
- Houston, TX89 štúdií
- New York City, NY69 štúdií
- Boston, MA61 štúdií
- Los Angeles, CA50 štúdií
- Nashville, TN49 štúdií
- Arlington, VA46 štúdií
- Philadelphia, PA44 štúdií
- Columbus, OH39 štúdií
- St. Louis, MO38 štúdií
- Chicago, IL36 štúdií
- San Antonio, TX31 štúdií
- Cleveland, OH30 štúdií
Iné štúdie v San Diego
- Nemalobunkový karcinóm pľúc48 štúdií
- Rakovina prsníka41 štúdií
- Rakovina (všetky typy)32 štúdií
- Rakovina prostaty31 štúdií
- Metastatická rakovina30 štúdií
- Kolorektálny karcinóm25 štúdií
- Rakovina pankreasu24 štúdií
- Rakovina pľúc23 štúdií
- Obézita23 štúdií
- Srdcové zlyhanie23 štúdií
- Depresia21 štúdií
- Melanóm18 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.